The sweden pharmaceutical market size is expected to grow from USD 5.91 billion in 2025 to USD 6.21 billion in 2026 and is forecast to reach USD 7.96 billion by 2031 at 5.08% CAGR over 2026-2031. This report Segments the Industry Into by ATC/Therapeutic Class (Cardiovascular System, Dermatological, Genito Urinary System and Sex Hormones, Anti-Infective for Systemic Use, Antineoplastic and Immunomodulating Agents, Musculoskeletal System, Nervous System, Respiratory System, and More), by Drug Type (Branded, Generic), and by Prescription Type (Prescription Drugs (Rx), Over the Counter (OTC) Drugs).
Market leadership is unlikely to change abruptly, but dermatology growth could narrow the gap with cardiovascular lines by 2031. Expansion in oncology and dermatology underscores Sweden’s orientation toward high-complexity care, which in turn supports premium pricing and trial activity. The strategic spread of therapy classes fosters resilience for the Sweden pharmaceutical market against single-segment shocks, giving manufacturers multiple entry points anchored in clearly defined clinical guidelines.
Branded products maintained a 70.55% grip on 2025 sales, reflecting clinicians’ preference for evidence-led outcomes and a reimbursement model that rewards genuine innovation. Specialty biologics and orphan drugs extend exclusivity windows, insulating premium lines from immediate biosimilar or generic threats. TLV’s health-technology assessments, which place clinical value ahead of mere cost minimization, reinforce brand durability for therapies targeting unmet needs.
Generics, however, accelerate at 6.71% CAGR as reference pricing and mandatory substitution sharpen price competition. The effect is most pronounced in cardiovascular and central-nervous-system drugs where therapeutic interchangeability is high. Biosimilar adoption remains selective, especially in oncology where switching hesitancy endures. The interplay of these forces cultivates a two-tier market: high-value specialty brands at the upper end, and commoditized small-molecule generics at the base, together forming a balanced yet dynamic Sweden pharmaceutical market
Sweden Pharmaceutical Market Trends and Insights
Growing Oncology-Drug Spend Driven by Aging & Lifestyle Change
Sweden’s 65-plus demographic is on course to hit 23% of the population by 2030, intensifying the national oncology bill. Pharmaceutical costs are projected to climb from SEK 38.7 billion in 2024 to SEK 46.4 billion in 2028, with oncology drugs rising fastest. Higher incidence of lung and colorectal cancers linked to lifestyle factors magnifies the need for targeted therapies and immuno-oncology agents. Universal access guarantees uptake of novel CAR-T and precision-medicine products, and richly linked national health registries provide real-world evidence that reinforces Sweden as a preferred location for global oncology trials. These dynamics collectively lift the Sweden pharmaceutical market by deepening demand for premium cancer treatments.National Life-Science Strategy Funding Translational Research
Government backing totaling SEK 3.1 billion through 2030 underwrites the SciLifeLab & Wallenberg program, which recruits 185 PhDs and expands data-driven life-science platforms. Prioritized fields include cell biology, precision medicine, and infection epidemiology, giving pharmaceutical developers an ecosystem for AI-enabled drug discovery. Funding also supports advanced-therapy development centers, evidenced by 48 active ATMP trials that generate regulatory knowledge and entice multinational R&D investment. The initiative enriches human capital and infrastructure, bolstering Sweden pharmaceutical market growth via accelerated bench-to-bedside cycles.Stricter Price-Pressure from TLV Reference-Pricing Updates
TLV’s international price benchmarking now places Swedish non-generic prices sixth lowest in Europe, while generics are the cheapest among 19 countries. The product-of-the-month system mandates substitution to the lowest-cost option, eroding margins for innovators. A new co-payment ceiling of SEK 3,800 from July 2025 signals unwavering cost-containment. Collectively these measures temper revenue expansion within the Sweden pharmaceutical market and compel firms to validate premium pricing through superior outcomes.Other drivers and restraints analyzed in the detailed report include:
- Accelerated Approval Pathway for ATMPs & Orphan Drugs
- Hospital Procurement Reforms Favor Value-Based Contracts
- Skilled-Labour Shortage in Biomanufacturing Facilities
Segment Analysis
The cardiovascular system category delivered 15.10% of the 2025 Sweden pharmaceutical market, supported by nationwide cardiac-care protocols and an aging population that sustains use of antihypertensives, anticoagulants, and lipid modulators. Antineoplastic and immunomodulating agents follow closely, boosted by the national cancer strategy and expedited approvals. Dermatologicals, while smaller in absolute terms, post a 6.12% CAGR that outpaces all other classes due to rising incidence of inflammatory skin diseases and greater biologic uptake. Sweden’s antimicrobial stewardship keeps anti-infective volumes flat, yet sustained hospital demand maintains a stable contribution. Respiratory therapies face smoking-rate declines, but gains in biologic asthma treatments balance volume attrition. Musculoskeletal, genito-urinary, and specialized hospital drugs together carve out a diverse tail of opportunity, especially where orphan status or niche clinical needs apply.Market leadership is unlikely to change abruptly, but dermatology growth could narrow the gap with cardiovascular lines by 2031. Expansion in oncology and dermatology underscores Sweden’s orientation toward high-complexity care, which in turn supports premium pricing and trial activity. The strategic spread of therapy classes fosters resilience for the Sweden pharmaceutical market against single-segment shocks, giving manufacturers multiple entry points anchored in clearly defined clinical guidelines.
Branded products maintained a 70.55% grip on 2025 sales, reflecting clinicians’ preference for evidence-led outcomes and a reimbursement model that rewards genuine innovation. Specialty biologics and orphan drugs extend exclusivity windows, insulating premium lines from immediate biosimilar or generic threats. TLV’s health-technology assessments, which place clinical value ahead of mere cost minimization, reinforce brand durability for therapies targeting unmet needs.
Generics, however, accelerate at 6.71% CAGR as reference pricing and mandatory substitution sharpen price competition. The effect is most pronounced in cardiovascular and central-nervous-system drugs where therapeutic interchangeability is high. Biosimilar adoption remains selective, especially in oncology where switching hesitancy endures. The interplay of these forces cultivates a two-tier market: high-value specialty brands at the upper end, and commoditized small-molecule generics at the base, together forming a balanced yet dynamic Sweden pharmaceutical market
Complete Report Scope:
- By ATC / Therapeutic Class
- Cardiovascular System
- Dermatological
- Genito-Urinary & Sex Hormones
- Anti-infectives (Systemic)
- Antineoplastic & Immunomodulating Agents
- Musculoskeletal System
- Nervous System
- Respiratory System
- Other Classes
- By Drug Type
- Branded
- Generic
- By Prescription Type
- Prescription (Rx)
- Over-the-Counter (OTC)
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
List of Companies Covered in this Report:
- Abbvie
- Amgen
- AstraZeneca
- BioArctic AB
- Camurus AB
- Eli Lilly and Company
- Roche
- GlaxoSmithKline
- Janssen-Cilag AB (Johnson & Johnson)
- Novartis
- Novo Nordisk
- Orexo
- Pfizer
- Recipharm
- Sandoz Group
- Sanofi
- Swedish Orphan Biovitrum
- Teva Sweden AB
- Xbrane Biopharma AB
- Orifarm Group
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
Table of Contents
1 Introduction
4 Market Landscape
5 Market Size & Growth Forecasts
6 Competitive Landscape
7 Market Opportunities & Future Outlook
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie Inc.
- Amgen Inc.
- AstraZeneca plc
- BioArctic AB
- Camurus AB
- Eli Lilly and Company
- F. Hoffmann-La Roche AG
- GSK plc
- Janssen-Cilag AB (Johnson & Johnson)
- Novartis AG
- Novo Nordisk A/S
- Orexo AB
- Pfizer Inc.
- Recipharm AB
- Sandoz International GmbH
- Sanofi S.A.
- Swedish Orphan Biovitrum AB (Sobi)
- Teva Sweden AB
- Xbrane Biopharma AB
- Orifarm Group A/S
